281 related articles for article (PubMed ID: 28925400)
1. The HIF and other quandaries in VHL disease.
Tarade D; Ohh M
Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
[TBL] [Abstract][Full Text] [Related]
2. Algorithmic assessment of missense mutation severity in the Von-Hippel Lindau protein.
Fields FR; Suresh N; Hiller M; Freed SD; Haldar K; Lee SW
PLoS One; 2020; 15(11):e0234100. PubMed ID: 33151962
[TBL] [Abstract][Full Text] [Related]
3. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
[TBL] [Abstract][Full Text] [Related]
4. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.
López-Jiménez E; Gómez-López G; Leandro-García LJ; Muñoz I; Schiavi F; Montero-Conde C; de Cubas AA; Ramires R; Landa I; Leskelä S; Maliszewska A; Inglada-Pérez L; de la Vega L; Rodríguez-Antona C; Letón R; Bernal C; de Campos JM; Diez-Tascón C; Fraga MF; Boullosa C; Pisano DG; Opocher G; Robledo M; Cascón A
Mol Endocrinol; 2010 Dec; 24(12):2382-91. PubMed ID: 20980436
[TBL] [Abstract][Full Text] [Related]
5. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract][Full Text] [Related]
6. An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.
Gossage L; Pires DE; Olivera-Nappa Á; Asenjo J; Bycroft M; Blundell TL; Eisen T
Hum Mol Genet; 2014 Nov; 23(22):5976-88. PubMed ID: 24969085
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia inducible factor signaling in breast tumors controls spontaneous tumor dissemination in a site-specific manner.
Todd VM; Vecchi LA; Clements ME; Snow KP; Ontko CD; Himmel L; Pinelli C; Rafat M; Johnson RW
Commun Biol; 2021 Sep; 4(1):1122. PubMed ID: 34556788
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol accumulation in ccRCC: the role of ccRCC-initiating VHL-HIFα pathway.
Mohtar MA; Hasanah Mohd Yusuf SN; Syafruddin SE
EBioMedicine; 2024 May; 103():105112. PubMed ID: 38599011
[No Abstract] [Full Text] [Related]
9. pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases.
Hwang IY; Roe JS; Seol JH; Kim HR; Cho EJ; Youn HD
Mol Cells; 2012 Feb; 33(2):195-201. PubMed ID: 22286234
[TBL] [Abstract][Full Text] [Related]
10. State of the science: an update on renal cell carcinoma.
Jonasch E; Futreal PA; Davis IJ; Bailey ST; Kim WY; Brugarolas J; Giaccia AJ; Kurban G; Pause A; Frydman J; Zurita AJ; Rini BI; Sharma P; Atkins MB; Walker CL; Rathmell WK
Mol Cancer Res; 2012 Jul; 10(7):859-80. PubMed ID: 22638109
[TBL] [Abstract][Full Text] [Related]
11. Oxygen-Mediated Suppression of CD8+ T Cell Proliferation by Macrophages: Role of Pharmacological Inhibitors of HIF Degradation.
Gojkovic M; Cunha PP; Darmasaputra GS; Barbieri L; Rundqvist H; Veliça P; Johnson RS
Front Immunol; 2021; 12():633586. PubMed ID: 34054802
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism.
Rankin EB; Rha J; Selak MA; Unger TL; Keith B; Liu Q; Haase VH
Mol Cell Biol; 2009 Aug; 29(16):4527-38. PubMed ID: 19528226
[TBL] [Abstract][Full Text] [Related]
13. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.
Metallo CM; Gameiro PA; Bell EL; Mattaini KR; Yang J; Hiller K; Jewell CM; Johnson ZR; Irvine DJ; Guarente L; Kelleher JK; Vander Heiden MG; Iliopoulos O; Stephanopoulos G
Nature; 2011 Nov; 481(7381):380-4. PubMed ID: 22101433
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulators: multifunctional proteins modulating hypoxia-inducible factor-α protein stability and activity.
Luo W; Wang Y
Cell Mol Life Sci; 2018 Mar; 75(6):1043-1056. PubMed ID: 29032501
[TBL] [Abstract][Full Text] [Related]
15. HIF2a inhibitors for the treatment of VHL disease.
Metelo AM; Noonan H; Iliopoulos O
Oncotarget; 2015 Sep; 6(27):23036-7. PubMed ID: 26325097
[No Abstract] [Full Text] [Related]
16. VHL and Hypoxia Signaling: Beyond HIF in Cancer.
Zhang J; Zhang Q
Biomedicines; 2018 Mar; 6(1):. PubMed ID: 29562667
[TBL] [Abstract][Full Text] [Related]
17. Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina.
Wang H; Shepard MJ; Zhang C; Dong L; Walker D; Guedez L; Park S; Wang Y; Chen S; Pang Y; Zhang Q; Gao C; Wong WT; Wiley H; Pacak K; Chew EY; Zhuang Z; Chan CC
Cancer Res; 2018 Mar; 78(5):1266-1274. PubMed ID: 29301791
[TBL] [Abstract][Full Text] [Related]
18. Consequences of VHL Loss on Global DNA Methylome.
Robinson CM; Lefebvre F; Poon BP; Bousard A; Fan X; Lathrop M; Tost J; Kim WY; Riazalhosseini Y; Ohh M
Sci Rep; 2018 Feb; 8(1):3313. PubMed ID: 29463811
[TBL] [Abstract][Full Text] [Related]
19. HIF Inhibitors: Status of Current Clinical Development.
Fallah J; Rini BI
Curr Oncol Rep; 2019 Jan; 21(1):6. PubMed ID: 30671662
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
